- Home
- JHS vs XGN Comparison
JHS vs XGN Comparison
Compare JHS & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHS
- XGN
- Stock Information
- Founded
- JHS 1973
- XGN 2002
- Country
- JHS United States
- XGN United States
- Employees
- JHS N/A
- XGN N/A
- Industry
- JHS Finance Companies
- XGN Medical Specialities
- Sector
- JHS Finance
- XGN Health Care
- Exchange
- JHS Nasdaq
- XGN Nasdaq
- Market Cap
- JHS 131.4M
- XGN 138.3M
- IPO Year
- JHS N/A
- XGN 2019
- Fundamental
- Price
- JHS $11.68
- XGN $9.63
- Analyst Decision
- JHS
- XGN Strong Buy
- Analyst Count
- JHS 0
- XGN 5
- Target Price
- JHS N/A
- XGN $12.40
- AVG Volume (30 Days)
- JHS 32.8K
- XGN 192.7K
- Earning Date
- JHS 01-01-0001
- XGN 11-11-2025
- Dividend Yield
- JHS 3.96%
- XGN N/A
- EPS Growth
- JHS N/A
- XGN N/A
- EPS
- JHS 0.02
- XGN N/A
- Revenue
- JHS N/A
- XGN $58,862,000.00
- Revenue This Year
- JHS N/A
- XGN $22.28
- Revenue Next Year
- JHS N/A
- XGN $14.03
- P/E Ratio
- JHS $553.50
- XGN N/A
- Revenue Growth
- JHS N/A
- XGN 3.89
- 52 Week Low
- JHS $9.76
- XGN $2.38
- 52 Week High
- JHS $11.25
- XGN $10.34
- Technical
- Relative Strength Index (RSI)
- JHS 57.26
- XGN 54.06
- Support Level
- JHS $11.53
- XGN $8.97
- Resistance Level
- JHS $11.95
- XGN $10.28
- Average True Range (ATR)
- JHS 0.14
- XGN 0.42
- MACD
- JHS 0.00
- XGN -0.12
- Stochastic Oscillator
- JHS 51.75
- XGN 50.38
About JHS John Hancock Income Securities Trust
John Hancock Income Securities Trust is a United States-based closed-ended diversified management investment company. Its primary objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.